From the ASN 2016, Philadelphia: TauroLock™-U25.000 vs. Citrate 4%
In a randomized controlled trial from Austria with 106 haemodialysis patients (Winnicki, W. and Sengoelge, G., JASN 2016,27:TH-OR 127) which was presented during the ASN meeting 2016 in Philadelphia a locking regimen with TauroLockTM-Hep500 twice weekly and TauroLockTM-U25.000 once weekly (before the long interval) was compared to 4% Citrate (CitraFlowTM) three times weekly.
The TauroLock™ 2+1 regimen was significantly superior to 4% Citrate in all aspects investigated:
|
|
TaurolockTM 2+1 |
4% Citrate |
p-value |
|
Catheter days |
8982 |
6708 |
|
|
Catheter-related bloodstream infections (/1000 catheter days)
|
0.67 |
2.6 |
0.003 |
|
Catheter dysfunction (/1000 catheter days) |
18.7 |
44.3 |
0.001 |
|
Alteplase intervention (/1000 catheter days) |
3.8 |
38 |
0.001 |
The results of this study show that 4% Citrate is no alternative to TauroLock™ neither regarding infection prevention nor maintenance of patency.